Short-term effects of two continuous combined oestrogen-progestogen therapies on several cardiovascular risk markers in healthy postmenopausal women: A randomised controlled trial
| Autor: | Alyde T. de Kraker, Marius J. van der Mooren, R.G.V. Smolders, Peter Kenemans, Maurice V.A.M. Kroeks |
|---|---|
| Přispěvatelé: | Obstetrics and gynaecology, ICaR - Ischemia and repair |
| Rok vydání: | 2009 |
| Předmět: |
Time Factors
Homocysteine medicine.medical_treatment Dydrogesterone Gastroenterology chemistry.chemical_compound Risk Factors Medicine Medroxyprogesterone acetate Fibrinolysin Insulin-Like Growth Factor I biology Endothelin-1 Estradiol Estrogen Replacement Therapy Obstetrics and Gynecology Factor VII Middle Aged Menopause Postmenopause Drug Combinations C-Reactive Protein Cardiovascular Diseases Tissue Plasminogen Activator Female medicine.drug Adult medicine.medical_specialty medicine.drug_class Medroxyprogesterone Acetate Internal medicine Plasminogen Activator Inhibitor 1 Humans Antigens alpha-2-Antiplasmin Progestogen business.industry C-reactive protein Fibrinogen medicine.disease Endocrinology Reproductive Medicine chemistry Estrogen biology.protein business Biomarkers Blood sampling |
| Zdroj: | de Kraker, A T, Kenemans, P, Smolders, R G V, Kroeks, M V A M & van der Mooren, M J 2009, ' Short-term effects of two continuous combined oestrogen-progestogen therapies on several cardiovascular risk markers in healthy postmenopausal women: A randomised controlled trial ', European Journal of Obstetrics and Gynecology and Reproductive Biology, vol. 142, no. 2, pp. 139-144 . https://doi.org/10.1016/j.ejogrb.2008.10.007 European Journal of Obstetrics and Gynecology and Reproductive Biology, 142(2), 139-144. Elsevier Ireland Ltd |
| ISSN: | 0301-2115 |
| Popis: | Objective To compare the short-term effects of two oral continuous combined oestrogen–progestogen treatment regimens on blood concentrations of several cardiovascular risk markers in healthy postmenopausal women. Study design In a 12-week randomised controlled study, 48 healthy non-hysterectomised postmenopausal women, aged 41–58 years, received either no treatment (control group; n = 16), or daily oral continuous combined treatment with 1 mg micronised 17β-oestradiol plus 5 mg dydrogesterone (E/D group; n = 18) or 0.625 mg conjugated equine oestrogens plus 5 mg medroxyprogesterone acetate (CEE/MPA group; n = 14). Fasting blood sampling was performed at baseline and after 12 weeks of follow-up. Results Compared with the control group, 12-week treatment with E/D or CEE/MPA reduced fibrinogen (−7.7%, p = 0.004 and −3.3%, p = 0.083, respectively), factor VII-act (−8.7%, p = 0.14 and −9.7%, p = 0.06, respectively), homocysteine (−20.5%, p = 0.02 and −26.7%, p = 0.005, respectively), and IGF-1 (−27.9%, p p = 0.002, respectively), but increased factor VII-ag (+10.1%, p = 0.03 and +4.4%, p = 0.46, respectively), endothelin-1 (+15.2%, p = 0.12 and +20.0%, p = 0.13, respectively) and C-reactive protein (+88.8%, p = 0.18 and +71.0%, p = 0.44, respectively). Fibrinolytic factors were not affected by either hormone therapy (HT). Conclusions Short-term oral continuous combined therapy with oestradiol/dydrogesterone and conjugated equine oestrogens/medroxyprogesterone acetate had comparable effects on the investigated cardiovascular risk markers. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect